DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC)
CUSIP: 25253X207
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Voting Common Shares, no par value
- Shares outstanding
- 52,272,727
- Total 13F shares
- 8,764,697
- Share change
- +1,246,896
- Total reported value
- $34,183,334
- Price per share
- $3.90
- Number of holders
- 58
- Value change
- +$4,951,594
- Number of buys
- 39
- Number of sells
- 25
Quarterly Holders Quick Answers
What is CUSIP 25253X207?
CUSIP 25253X207 identifies DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 25253X207:
Top shareholders of DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Leon G. Cooperman |
13F
|
Individual |
3.1%
|
1,625,000
|
$6,158,750 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.6%
|
1,351,467
|
$5,122,060 | — | 31 Mar 2025 | |
| David J. Wambeke |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
1,304,228
mixed-class rows
|
$3,420,969 | — | 01 Jun 2025 | |
| FIRST MANHATTAN CO. LLC. |
13F
|
Company |
1.2%
|
606,435
|
$2,298,389 | — | 31 Mar 2025 | |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE |
13F
|
Company |
1.1%
|
600,000
|
$2,274,000 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.1%
|
556,593
|
$2,109,487 | — | 31 Mar 2025 | |
| Bleichroeder LP |
13F
|
Company |
0.73%
|
382,317
|
$1,448,981 | — | 31 Mar 2025 | |
| Richard D. Pilnik |
3/4/5
|
Director |
—
class O/S missing
|
591,597
|
$1,440,505 | — | 07 Apr 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.64%
|
336,880
|
$1,276,775 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.6%
|
315,741
|
$1,196,928 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.34%
|
177,280
|
$671,891 | — | 31 Mar 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.3%
|
155,300
|
$588,587 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.3%
|
155,031
|
$588,000 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.23%
|
121,802
|
$461,630 | — | 31 Mar 2025 | |
| Dietrich John Pauls |
3/4/5
|
President & CEO, Director |
—
mixed-class rows
|
737,182
mixed-class rows
|
$445,155 | — | 01 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.2%
|
106,350
|
$403,066 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.2%
|
103,583
|
$392,580 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.19%
|
100,669
|
$381,536 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.16%
|
85,029
|
$322,260 | — | 31 Mar 2025 | |
| Blue Trust, Inc. |
13F
|
Company |
0.13%
|
69,122
|
$261,972 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.11%
|
56,703
|
$214,000 | — | 31 Mar 2025 | |
| Scott Kellen |
3/4/5
|
CFO & Secretary |
—
mixed-class rows
|
289,580
mixed-class rows
|
$209,562 | — | 01 Jun 2025 | |
| Amy L. Burroughs |
3/4/5
|
Director |
—
class O/S missing
|
73,288
|
$205,206 | — | 03 Jan 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.1%
|
53,700
|
$203,523 | — | 31 Mar 2025 | |
| CATALYST FINANCIAL PARTNERS LLC |
13F
|
Company |
0.07%
|
38,457
|
$145,752 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.07%
|
36,929
|
$139,961 | — | 31 Mar 2025 | |
| Richard Kuntz |
3/4/5
|
Director |
—
mixed-class rows
|
70,657
mixed-class rows
|
$129,332 | — | 01 Jun 2025 | |
| Harry W. Alcorn Jr. |
3/4/5
|
SVP, Clinical Operations |
—
class O/S missing
|
43,981
|
$123,147 | — | 15 Sep 2021 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.06%
|
30,397
|
$115,203 | — | 31 Mar 2025 | |
| Meridian Wealth Management, LLC |
13F
|
Company |
0.06%
|
28,816
|
$109,213 | — | 31 Mar 2025 | |
| Jain Global LLC |
13F
|
Company |
0.05%
|
27,679
|
$104,903 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.05%
|
26,000
|
$98,540 | — | 31 Mar 2025 | |
| World Investment Advisors |
13F
|
Company |
0.05%
|
25,650
|
$97,214 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.05%
|
25,270
|
$95,773 | — | 31 Mar 2025 | |
| OMERS ADMINISTRATION Corp |
13F
|
Company |
0.05%
|
24,300
|
$92,097 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.04%
|
19,339
|
$73,295 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.04%
|
18,829
|
$71,361 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.03%
|
18,270
|
$69,243 | — | 31 Mar 2025 | |
| Stonebridge Capital Advisors LLC |
13F
|
Company |
0.03%
|
17,500
|
$66,325 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
16,765
|
$63,539 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.03%
|
16,483
|
$62,469 | — | 31 Mar 2025 | |
| Cornerstone Wealth Management, LLC |
13F
|
Company |
0.03%
|
16,250
|
$61,588 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.03%
|
15,667
|
$59,378 | — | 31 Mar 2025 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.03%
|
15,560
|
$58,972 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.03%
|
15,173
|
$57,506 | — | 31 Mar 2025 | |
| LMR Partners LLP |
13F
|
Company |
0.03%
|
15,167
|
$57,483 | — | 31 Mar 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.03%
|
13,343
|
$51,000 | — | 31 Mar 2025 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.03%
|
13,335
|
$50,540 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.03%
|
13,253
|
$50,229 | — | 31 Mar 2025 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.02%
|
12,480
|
$47,299 | — | 31 Mar 2025 |
Institutional Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q2 2025
As of 30 Jun 2025,
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,764,697 shares.
The largest 10 holders included
COOPERMAN LEON G, VANGUARD GROUP INC, BlackRock, Inc., PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE, GEODE CAPITAL MANAGEMENT, LLC, FIRST MANHATTAN CO. LLC., Bleichroeder LP, NORTHERN TRUST CORP, STATE STREET CORP, and MORGAN STANLEY.
This page lists
58
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
57
Q2 2025 holders
58
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.